Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VAY736 drug product comparability in rheumatoid arthritis
NCT03574545Phase 1Completed
- Sponsor
- Novartis
- Start
- Dec 2018
- Primary completion
- Jul 2024
- Modality
- Monoclonal Antibodies
- Countries
- 2
01
Overview
Phase 1, randomised, open-label trial of ianalumab in rheumatoid arthritis (RA) (2 arms), sponsored by Novartis. Primary endpoints: Adverse Events at 112 weeks, Area Under the Curve During Dosing Interval at Steady State at 12 weeks and 1 more. Started Dec 2018; status: completed.
02
Drugs
ianalumab
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT03574545.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03574545.